Boxer Capital Management, LLC
Reported holdings as of Q2 2026, from 7 quarterly filings.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| TANGO THERAPEUTICS INC | TNGX | $340.0M | 10,876,219 | -4.27pp | 7q | HELD | |
| REVOLUTION MEDICINES INC | RVMD | $93.6M | 500,000 | +0.67pp | 7q | HELD | |
| ABIVAX SA | ABVX | $80.6M | 605,000 | +3.15pp | 4q | +202.5%+$54.0M | |
| UNIQURE NV | QURE | $69.2M | 1,503,300 | +3.79pp | 7q | +127.1%+$38.8M | |
| KODIAK SCIENCES INC | KOD | $57.6M | 1,477,600 | -2.48pp | 7q | +8.6%+$4.5M | |
| KYMERA THERAPEUTICS INC | KYMR | $49.2M | 429,100 | +0.11pp | 7q | +30.4%+$11.5M | |
| DEFINIUM THERAPEUTICS INC | DFTX | $47.0M | 998,500 | +2.05pp | 2q | +66.8%+$18.8M | |
| REPLIMUNE GROUP INC | REPL | $44.1M | 3,983,000 | +2.14pp | 7q | +239.0%+$31.1M | |
| CELCUITY INC | CELC | $43.6M | 416,530 | -0.09pp | 4q | +85.1%+$20.0M | |
| Q32 BIO INC | QTTB | $40.1M | 3,149,310 | - | new | NEW | |
| CAPRICOR THERAPEUTICS INC | CAPR | $33.6M | 1,395,156 | +0.18pp | 3q | +136.5%+$19.4M | |
| PRECIGEN INC | PGEN | $29.4M | 5,150,000 | +0.43pp | 4q | +47.1%+$9.4M | |
| CORCEPT THERAPEUTICS INC | CORT | $29.2M | 335,500 | +0.87pp | 2q | +34.2%+$7.4M | |
| SURROZEN INC | SRZN | $27.0M | 1,105,683 | -0.90pp | 3q | +44.3%+$8.3M | |
| PROTAGONIST THERAPEUTICS INC | PTGX | $20.8M | 170,000 | -0.78pp | 5q | HELD | |
| VIR BIOTECHNOLOGY INC | VIR | $19.0M | 1,866,000 | -0.76pp | 3q | HELD | |
| VAXCYTE INC | PCVX | $18.9M | 325,000 | -1.06pp | 2q | HELD | |
| UROGEN PHARMA LTD | URGN | $18.4M | 500,000 | +0.21pp | 5q | HELD | |
| CORVUS PHARMACEUTICALS INC | CRVS | $16.4M | 1,100,000 | -0.88pp | 2q | HELD | |
| PTC THERAPEUTICS INC | PTCT | $16.3M | 200,000 | -0.56pp | 4q | HELD | |
| PRAXIS PRECISION MEDICINES I | PRAX | $15.6M | 46,457 | -0.79pp | 3q | HELD | |
| AMYLYX PHARMACEUTICALS INC | AMLX | $14.4M | 800,000 | -0.38pp | 7q | HELD | |
| OCULAR THERAPEUTIX INC | OCUL | $12.8M | 1,300,000 | +0.57pp | 2q | +271.4%+$9.3M | |
| OPUS GENETICS INC | IRD | $11.6M | 2,815,000 | -0.47pp | 2q | +25.1%+$2.3M | |
| PALISADE BIO INC | PALI | $10.0M | 4,799,875 | -0.35pp | 3q | HELD | |
| APOGEE THERAPEUTICS INC | APGE | $9.3M | 70,000 | -0.07pp | 4q | HELD | |
| SPYRE THERAPEUTICS INC | SYRE | $8.9M | 100,000 | - | new | NEW | |
| COGENT BIOSCIENCES INC | COGT | $8.7M | 225,000 | -0.48pp | 3q | HELD | |
| CYTOKINETICS INC | CYTK | $8.5M | 100,000 | -0.22pp | 4q | HELD | |
| RELAY THERAPEUTICS INC | RLAY | $8.4M | 450,000 | - | new | NEW | |
| CRESCENT BIOPHARMA INC. | CBIOXXXX | $8.2M | 453,686 | -0.48pp | 2q | HELD | |
| CONTINEUM THERAPEUTICS INC | CTNM | $8.1M | 494,000 | -0.24pp | 3q | HELD | |
| KAZIA THERAPEUTICS LTD | KZIA | $7.9M | 560,000 | - | new | NEW | |
| SHATTUCK LABS INC | STTK | $6.9M | 1,000,000 | - | new | NEW | |
| AVALO THERAPEUTICS INC | AVTX | $6.9M | 375,000 | -0.07pp | 4q | +25.0%+$1.4M | |
| FORTE BIOSCIENCES INC | FBRX | $5.8M | 274,500 | - | new | NEW | |
| RELMADA THERAPEUTICS INC | RLMD | $5.8M | 842,106 | -0.33pp | 2q | HELD | |
| MOONLAKE IMMUNOTHERAPEUTICS | MLTX | $5.4M | 275,000 | -0.27pp | 4q | HELD | |
| ZURA BIO LTD | ZURA | $5.3M | 900,000 | -0.30pp | 3q | HELD | |
| CYBIN INC | HELP | $5.2M | 790,000 | -0.01pp | 3q | +23.4%+$991.5K | |
| ODYSSEY THERAPEUTICS INC | ODTX | $5.1M | 275,000 | - | new | NEW | |
| IMMATICS N.V | IMTX | $4.8M | 475,000 | - | new | NEW | |
| FAETH THERAPEUTICS INC | FTH | $4.5M | 180,505 | - | new | NEW | |
| STRUCTURE THERAPEUTICS INC | GPCR | $4.0M | 75,000 | -0.17pp | 3q | HELD | |
| ORIC PHARMACEUTICALS INC | ORIC | $3.8M | 350,000 | -0.01pp | 2q | +98.3%+$1.9M | |
| AN2 THERAPEUTICS INC | ANTX | $3.6M | 749,035 | -0.06pp | 2q | HELD | |
| NEUMORA THERAPEUTICS INC. | NMRA | $3.4M | 2,000,000 | - | new | NEW | |
| INOVIO PHARMACEUTICALS INC | INO | $3.1M | 2,844,994 | -0.31pp | 4q | +20.0%+$522.4K | |
| ALLOGENE THERAPEUTICS INC | ALLO | $3.1M | 1,500,000 | -0.64pp | 2q | -45.0%-$2.5M | |
| SOLID BIOSCIENCES INC | SLDB | $3.0M | 300,000 | -0.06pp | 4q | HELD | |
| KARYOPHARM THERAPEUTICS INC | KPTI | $3.0M | 302,536 | flat | 3q | HELD | |
| CLENE INC | CLNN | $2.9M | 477,515 | -0.09pp | 3q | HELD | |
| SAREPTA THERAPEUTICS INC | SRPT | $2.7M | 150,000 | -0.23pp | 5q | HELD | |
| MAPLIGHT THERAPEUTICS INC | MPLT | $2.7M | 75,000 | - | new | NEW | |
| NURIX THERAPEUTICS INC | NRIX | $2.4M | 100,000 | -0.02pp | 7q | HELD | |
| LB PHARMACEUTICALS INC | LBRX | $2.3M | 70,000 | -0.06pp | 4q | HELD | |
| EDESA BIOTECH INC | EDSA | $1.7M | 205,000 | - | new | NEW | |
| INVIVYD INC | IVVD | $1.3M | 1,500,000 | -0.16pp | 3q | HELD | |
| UPSTREAM BIO INC | UPB | $1.0M | 150,000 | -0.10pp | 3q | HELD | |
| MILESTONE PHARMACEUTICALS IN | MIST | $893.3K | 666,666 | -0.04pp | 4q | HELD | |
| PEPGEN INC | PEPG | $491.2K | 272,892 | -0.03pp | 4q | HELD | |
| REGENXBIO INC | RGNX | $179.7K | 15,000 | flat | 2q | HELD | |
| SURROZEN INC | SRZNW | $1.1K | 66,666 | flat | 7q | HELD |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $1.3B | 95.7% |
| Healthcare Services | $43.6M | 3.3% |
| Not classified | $13.3M | 1.0% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $1.3B | 63 | 12 | 17 | 1 | 3 | 65.1% | 45 |
| Q1 2026 | $761.7M | 54 | 13 | 13 | 3 | 4 | 63.3% | 45 |
| Q4 2025 | $456.9M | 45 | 15 | 14 | 8 | 4 | 62.1% | 48 |
| Q3 2025 | $313.7M | 34 | 15 | 2 | 9 | 1 | 75.2% | 140 |
| Q2 2025 | $198.7M | 20 | 8 | 3 | 7 | 16 | 91.4% | 232 |
| Q1 2025 | $332.5M | 28 | 2 | 2 | 10 | 34 | 72.4% | 323 |
| Q4 2024 | $1.2B | 60 | 0 | 0 | 0 | 0 | 60.2% | 45 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.